Overview

VNP40101M and Temozolomide in Treating Patients With Progressive or Relapsed Malignant Glioma

Status:
Terminated
Trial end date:
2009-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as temozolomide and VNP40101M, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Temozolomide may also stop the growth of tumor cells by blocking blood flow to the tumor. PURPOSE: This phase I/II trial is studying the side effects and best dose of VNP40101M when given together with temozolomide and to see how well it works in treating patients with progressive or relapsed malignant glioma.
Phase:
Phase 1
Details
Lead Sponsor:
Northwestern University
Collaborator:
Vion Pharmaceuticals
Treatments:
Dacarbazine
Temozolomide